



FORM HDP-1449 (Based on Form PTO-1449)
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 1 of 6

ATTORNEY DOCKET NO.	SERIAL NO.
009884/US (Pfizer Ref. 27378/USA)	10/700,202
APPLICANT	
Joseph J. McDonald, et al.	
FILING DATE	GROUP
November 3, 2003	1624

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.	EFB	4,595,700	6/17/1986	Donald, et al.	514/616	
2.		5,451,676	9/19/1995	Whittaker, et al.	546/118	
3.		5,472,978	12/5/1995	Baker, et al.	514/443	
4.		5,475,138	12/12/1995	Pal, et al.	564/342	
5.		5,599,994	2/4/1997	Pal, et al.	564/355	
6.		5,932,595	8/3/1999	Bender, et al.	514/317	
7.		5,998,412	12/7/1999	Broka, et al.	514/250	
8.		6,013,649	1/11/2000	Freskos, et al.	514/237.8	
9.		6,300,514	10/09/2001	Takahashi, et al.	560/17	
10.	↓	6,372,758, including 9/3/01 Office action and 10/25/01 notice of allowance—	4/16/2002	DeCrescenzo, et al.	514/316	
11.		6,387,931 (withdrawn)	5/14/2002	Dack, et al.	514/318	
12.	EFB	6,448,250, including 9/5/01 Office action and 1/29/02 notice of allowance	9/10/2002	DeCrescenzo, et al.	514/252	
13.	EFB	6,492,367, including 7/3/02 notice of allowance	12/10/2002	DeCrescenzo, et al.	514/252	
14.	EFB	6,495,568	12/17/2002	Dack, et al.	514/318	
15.	EFB	6,683,078	1/27/2004	Barta, et al.	514/231.5	07/12/2002
16.	EFB	6,683,093	1/27/2004	Barta, et al.	514/316	11/21/2001
17.	EFB	6,689,794	2/10/2004	Freskos, et al.	514/318	05/10/2002

→ Patent #11 - withdrawn from issue.

Examiner: *E Bernhardt*

Date Considered:

11/28/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 327050953 US

FORM HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		00988/4/US (Pfizer Ref. 27378/USA)	10/700,202
		APPLICANT	
		Joseph J. McDonald, et al.	
Sheet 2 of 6		FILING DATE	GROUP
		November 3, 2003	1624

18.	<i>EFB</i>	6,800,646, including 12/19/02 and 7/22/03 Office actions, and 11/21/03 notice of allowance	10/5/2004	DeCrescenzo, et al.	514/316	09/30/2002
19.		Appl. No. 09/311,837		Barta, et al.		05/14/1999
20.	<i>FB</i>	Publ. No. 2004- 0024024 A1 (Appl. No. 10/291,983)		Freskos, et al.	514/326	11/12/2002
21.		Appl. No. 10/887,450, including pending claims (as of January 31, 2005) and 12/2/04 Office action		Boehm, et al.		07/08/2004

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
22.	<i>EFB</i>	EP 0 266 182	5/4/1988	Europe	C07D 307/32		
23.		EP 0 336 354	10/11/1989	Europe	C07D 239/42		X
24.		EP 0 606 046	7/13/1994	Europe	C07D 213/42		
25.		EP 0 780 386	6/25/1997	Europe	C07D 309/08		
26.		EP 0 930 067	7/21/1999	Europe	A61K 31/40		
27.		EP 0 931 788	7/28/1999	Europe	C07C 311/03		
28.		EP 1 081 137	3/7/2001	Europe	C07D 211/96		
29.		GB 1,067,965	5/10/1967	Great Britain	C07D 499/00		
30.		GB 2,263,109	7/14/1993	Great Britain	C07D 409/04		
31.	↓	JP 4-338331	11/25/1992	Japan	A61K 31/365	partial	

Examiner: *E Benbrandt* Date Considered: *11/28/05*

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		00988/4/US (Pfizer Ref. 27378/USA)	10/700,202
		APPLICANT	
		Joseph J. McDonald, et al.	
Sheet 3 of 6		FILING DATE	GROUP
		November 3, 2003	1624

32.	<i>EB</i>	WO 90/05719 ✓	5/31/1990	PCT	C07C 323/62		
33.		WO 93/20047 ✓	10/14/1993	PCT	C07C 317/44		
34.		WO 94/02466 ✓	2/3/1994	PCT	C07D 221/14		
35.		WO 94/24140 ✓	10/27/1994	PCT	C07H 13/04		
36.		WO 95/04720 ✓	2/16/1995	PCT	C07D 209/42		
37.		WO 95/09841 ✓	4/13/1995	PCT	C07C 323/60		
38.		WO 95/13064 ✓	5/18/1995	PCT	A61K 31/415		
39.		WO 95/13289 ✓	5/18/1995	PCT	C07K 5/062		
40.		WO 95/29892 ✓	11/9/1995	PCT	C07D 207/327		
41.		WO 96/06074 ✓	2/29/1996	PCT	C07C 259/06		
42.		WO 96/11209 ✓	4/18/1996	PCT	C07K 5/06		
43.		WO 97/05865 ✓	2/20/1997	PCT	A61K 31/215		
44.		WO 97/20824 ✓	6/12/1997	PCT	C07D 241/04		
45.		WO 97/24117 ✓	7/10/1997	PCT	A61K 31/19		
46.		WO 97/48368 ✓	12/24/1997	PCT	A61K		
47.		WO 98/37877 ✓	9/31/1998	PCT	A61K 31/16		
48.		WO 98/38163 ✓	9/3/1998	PCT	C07C 323/60		
49.		WO 98/38859 ✓	9/11/1998	PCT	A01N 37/28		
50.		WO 98/39329 ✓	9/11/1998	PCT	C07D 413/12		
51.	↓	WO 99/09000 ✓	2/25/1999	PCT	C07C 235/00		

Examiner:

E Bernhard

Date Considered:

11/28/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		00988/4/US (Pfizer Ref. 27378/USA)	10/700,202
		APPLICANT	
		Joseph J. McDonald, et al.	
Sheet 4 of 6		FILING DATE	GROUP
		November 3, 2003	1624

52.	<i>E.B.</i>	WO 99/24399 ✓	5/20/1999	PCT	C07C 311/04		
53.		WO 99/25687 ✓	5/27/1999	PCT	C07D 211/66		
54.		WO 99/29667 ✓	6/17/1999	PCT	C07D 211/16		
55.		WO 99/42436 ✓	8/26/1999	PCT	C07C 239/14		
56.		WO 00/38717 ✓	6/7/2000	PCT	A61K 41/00		
57.		WO 00/46221 ✓	8/10/2000	PCT	C07D 405/12		
58.		WO 00/50396 ✓	8/31/2000	PCT	C07D 211/66		
59.		WO 00/59874 ✓	10/12/2002	PCT	C07C 259/06		
60.		WO 00/69819 ✓	11/23/2002	PCT	C07D 211/16		
61.		WO 00/69821 ✓	11/23/2000	PCT	C07D 211/66		
62.		WO 00/74681 ✓	12/14/2000	PCT	A61K 31/451		
63.		WO 02/092588 ✓	11/21/2002	PCT	C07D 309/08		
64.	↓	WO 03/007930 ✓	1/30/2003	PCT	A61K 31/166		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
65.	<i>E.B.</i>	Brown, P.D., "Synthetic Inhibitors of Matrix Metalloproteinases," in <i>Matrix Metalloproteinases</i> , pp. 243-61 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998).
66.		Dack, et al., "Preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related compounds as matrix metalloprotease inhibitors," CA 131:44740 (1999) [CA Plus Accession No. 1999:388166].
67.	↓	Denis et al., <i>Matrix metalloproteinase inhibitors: Present achievements and future prospects</i> , INVEST. NEW DRUGS, 15:175-185 (1997).

Examiner: *E Bernhardo* Date Considered: *11/28/05*

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		00988/4/US (Pfizer Ref. 27378/USA)	10/700,202
Sheet 5 of 6		APPLICANT	
		Joseph J. McDonald, et al.	
		FILING DATE	GROUP
		November 3, 2003	1624

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)			
Ref. Desig.	Examiner's Initials		
68.	EJB	Freije et al., <i>Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas</i> , J BIOL. CHEM., 269(24):16766-16773 (1994).	
69.		Gearing et al., <i>Processing of tumour necrosis factor-α precursor by metalloproteinases</i> , NATURE, 370:555-557 (1994).	
70.		Gu et al., <i>S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death</i> , SCIENCE, 297:1186-90 (2002).	
71.		Hughes, et al., <i>Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro</i> , BIOCHEM. J., 305:799-804 (1995).	
72.		10/9/2003 Search Report and 8/3/2004 Preliminary Examination Report for International Application No. PCT/US03/13123	
73.		Kenyon et al., <i>A model of angiogenesis in the mouse cornea</i> , INVEST. OPHTHALMOL. VIS. SCI., 37(8):1625-1632 (1996).	
74.		Knight et al., <i>A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases</i> , FEBS LETT., 296(3):263-266 (1992).	
75.		Kuzmic et al., <i>High-throughput enzyme kinetics: Simultaneous determination of tight-binding inhibition constants and enzyme concentration</i> , ANAL. BIOCHEM., 286(1):45-50 (2000).	
76.		Luckow et al., <i>Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in escherichia coli</i> , J. VIROL., 67:4566-4579 (1993).	
77.		Luckow, et al., "Insect Cell Expression Technology," in <i>Protein Engineering: Principles and Practice</i> , pp. 183-218 (John Wiley & Sons, Inc., New York, NY, Edited by J.L. Cleland et al., 1996)	
78.		McClure, et al., "Matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases," CA 131:125454 (1999) [CA Plus Accession No. 1999:468334].	
79.		McGeehan et al., <i>Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor</i> , NATURE, 370:558-561 (1994).	
80.		Mitchell et al., <i>Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage</i> , J. CLIN. INVEST. 97(3):761-768 (1996).	
81.	↓	Rasmussen et al., <i>Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat</i> , PHARMACOL. THER., 75(1):69-75 (1997).	

Examiner: *E. Bunnland* Date Considered: *11/28/05*

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		00988/4/US (Pfizer Ref. 27378/USA)	10/700,202
		APPLICANT	
		Joseph J. McDonald, et al.	
		FILING DATE	GROUP
		November 3, 2003	1624

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
82.	<i>FB</i>	Reboul et al., <i>The new collagenase, collagease-3, is expressed and synthesized by human chondrocytes but not by synoviocytes</i> , J. CLIN. INVEST., 97(9):2011-2019 (1996).
83.	<i>C</i>	Schwartz et al., <i>Synthetic inhibitors of bacterial and mammalian interstitial collagenases</i> , PROG. IN MED. CHEM., 29:271-334 (1992).
84.	<i>C</i>	Tang, B. L., <i>ADAMTS: A Novel Family of Extracellular Matrix Proteases</i> , INT. J. BIOCHEM. CELL BIO., 33(11):33-44 (2001).
85.	<i>C</i>	Woessner, J.F., "The Matrix Metalloprotease Family" in <i>Matrix Metalloproteinases</i> , pp.1-14 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998).

Examiner: *E Bernhard* Date Considered: *11/28/05*

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.